PCYC â Q2 CC â Introducing The Ibrutinib Commercial Powerhouse; Raising BUY LIMIT and TARGET PRICE â As the days countdown to the final FDA approval, PCYC has enlisted a truly impressive lineup to launch ibrutinib in the U.S. The company has prepared its sales, marketing and medical affairs departments, led by experienced industry executives[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.